

# Antibody Symposium

17 September 2012, Breakthrough Theatre, Matrix Level 4

Time	Details
9.45 – 10.00am	Registration
<b>Session 1 Chairperson – Professor Sir David Lane</b>	
10.00 – 10.15am	<b>Welcome Address by Sir David Lane</b> Chief Scientist, A*STAR & Director, p53Lab
10.15 – 10.55am	<b>Antibody Engineering Technologies for Next Generation Antibody Therapeutics</b> Dr Tomoyuki Igawa Research Scientist, Chugai Pharmaceutical Co., Ltd.
10.55 – 11.35am	<b>Antibody Drug Discovery Process in CPR based on Recycling &amp; Sweeping Antibody Technology</b> Dr Junichi Nezu Research Head, Chugai Pharmabody Research Pte. Ltd.
11.35 – 12.05pm	<b>The Derivation and Characterization of a Therapeutic Human Antibody for Dengue Virus Infection</b> Asst. Prof Paul MacAry Department of Microbiology and Immunology Programme, National University of Singapore
12.05 – 12.35pm	<b>Therapeutic Antibody Discovery Platform at SigN</b> Dr Cheng-I Wang Singapore Immunology Network
12.35 – 2.00pm	Lunch
<b>Session 2 Chairperson – TBC</b>	
2.00 – 2.30pm	<b>Antibodies to Treat a Pandemic – Influenza and Beyond</b> Dr Brendon Hanson DSO National Laboratories
2.30 – 3.00pm	<b>Generation of Antibodies Targeting Cell Surface Antigens on Stem Cells and Cancer Cells</b> Dr Tan Heng Liang delivered on behalf of Dr Andre Choo Bioprocessing Technology Institute
3.00 – 3.30pm	<b>ErbB2 and the Synergistic Binding of its Antibodies: In Silico Insights</b> Dr Gloria Fuentes Bioinformatics Institute
3.30 – 5.00pm	Networking Session

## Organisers:

p53 Laboratory, BMSI, A\*STAR, Singapore  
Chugai Pharmabody Research Pte Ltd, Singapore

